Ann: Multiple Patients Dosed in Topical Phase I/II Clinical Trial, page-70

very interesting. I had got the impression that recce had been approved for emergency access for quite some time but they always seemed to state if there was any news on emergency access it would be released via asx. I took that to mean it hadn't happened. Only other assumption is it didn't work I guess.
Even that is not such a big deal I guess, probably why they decided to target sepsis or burns. May be harder to target an internal area where the compound might reach lots of other areas before reaching the area being treated ie via oral application.